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Abstract
Polycyclic aromatic hydrocarbons (PAH) are mammary carcinogens in animal studies, and a few
epidemiologic studies have suggested a link between elevated levels of PAH-DNA adducts and breast
cancer incidence. An association between PAH-DNA adducts and survival among breast cancer cases
has not been previously reported. We conducted a survival analysis among women with newly
diagnosed invasive breast cancer between 1996 and 1997, enrolled in the Long Island Breast Cancer
Study Project. DNA was isolated from blood samples that were obtained from cases shortly after
diagnosis and before treatment, and assayed for PAH-DNA adducts using an ELISA. Among the
722 cases with PAH-DNA adduct measurements, 97 deaths (13.4%) from all causes and 54 deaths
(7.5%) due to breast cancer were reported to the National Death Index (NDI) by December 31, 2002.
Using Cox proportional hazards models and controlling for age at diagnosis, we did not find evidence
that all-cause mortality (hazard ratio (HR) = 0.88; 95% confidence interval (CI): 0.57–1.37), or breast
cancer mortality (HR = 1.20; 95% CI: 0.63–2.28) was strongly associated with detectable PAH-DNA
adduct levels compared with non-detectable adducts; additionally, no dose-response association was
observed. Among a subgroup with treatment data (n=520), adducts were associated with over a two-
fold higher mortality among those receiving radiation, but mortality for adducts was reduced among
hormone therapy users. Results from this large population-based study do not provide strong support
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for an association between detectable PAH-DNA adducts and survival among women with breast
cancer, except perhaps among those receiving radiation treatment.
Keywords
breast neoplasms; mortality; survival analysis; polycyclic aromatic hydrocarbons; environmental
health
INTRODUCTION
Polycyclic aromatic hydrocarbons (PAH) are ubiquitous environmental compounds formed
from incomplete combustion of carbon-containing materials, including coal, gas and cigarette
smoke. PAH exposure routes include inhalation, ingestion of PAH-containing food (e.g.,
grilled/smoked foods), and dermal absorption. Binding of PAH with DNA and consequent
adduct formation provide an opportunity for measuring body burden in human tissue (Santella
et al., 1999).
Several epidemiologic studies report an association between PAH-DNA adducts and breast
cancer incidence (Gammon et al., 2004; Gammon et al., 2002a; Li et al., 1996; Rundle et al.,
2000). In the Long Island Breast Cancer Study Project (LIBCSP) case-control analysis we
found a positive association between PAH-DNA adducts and breast cancer incidence
(OR=1.29, 95% CI: 1.05, 1.58) (Gammon et al., 2004). To date no studies have reported the
association between PAH-DNA adducts and survival.
We conducted a follow-up study to investigate the association between PAH-DNA adducts
and mortality due to all causes and to breast cancer-specific causes among the cohort of cases
participating in the LIBCSP (Gammon et al., 2002b).
METHODS
Study Population
For the parent LIBCSP case-control study (Gammon et al., 2002b) cases included 1,508 (82%
of eligible cases) English-speaking women residing in Nassau or Suffolk county on Long
Island, NY with newly diagnosed first primary breast cancer between August 1, 1996, and July
31, 1997. Cases ranged in age from 20 to 98 years at diagnosis, 94% are white, 4% are African
American, and 2% are of other race. Our analyses are restricted to cases with invasive breast
cancer (n=1,273).
The baseline, case-control questionnaire (Gammon et al., 2002b) was administered in-person
shortly after diagnosis and assessed demographic characteristics; medical history (including
family history of breast cancer); body size; physical activity; menstrual and reproductive
histories; exogenous hormone use; active and passive cigarette smoking; and alcohol
consumption. Medical records were abstracted for tumor characteristics including estrogen/
progesterone receptor (ER/PR) status.
Exposure Assessment and Laboratory Methods
Non-fasting blood samples of sufficient volume were collected from 722 invasive breast cancer
cases before treatment was administered and PAH-DNA adducts assayed using a competitive
ELISA. Laboratory methods were described previously (Gammon et al., 2004; Gammon et al.,
2002a). Briefly, two rounds of samples were run by the same laboratory (RMS) using the same
procedures and later pooled. PAH diol epoxide-DNA adducts were analyzed by competitive
ELISA using a method that has been described (Poirier et al., 1980; Santella et al., 1992). For
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analytical purposes, those samples with <15% inhibition were considered non-detectable and
assigned a value of 1/108, an amount midway between the lowest positive value and zero. For
Round 1 a positive control run with multiple batches of samples (n = 11) had a mean (±SD) of
20.3 (±5.0) with a CV of 25%. For Round 2 the mean value and standard deviation (SD) for
the positive control run with multiple batches was 7.8 (3.10)(n = 10). As an additional quality
control measure, samples were assayed in duplicate (10% for Round 1 and 17% for Round 2);
there was no significant difference in mean adduct levels (Round 1: mean difference = −0.60
(SD = 2.43); P = 0.60 by paired t test; Round 2: mean difference = −0.02 (SD = 3.24), paired
t-test p-value = 0.93).
Outcome Assessment
For the follow-up study (Sagiv et al., 2007), National Death Index (NDI) data were linked
during the period beginning with the date of diagnosis until December 31, 2002. Median
duration of follow-up for the 722 cases was 70.6 months (range, 4.6 – 88.6 months). Among
722 women with invasive breast cancer, there were 97 deaths (13.4%) due to all causes, of
which 54 deaths (7.5%) were due to breast cancer. Complete treatment regimen for the initial
breast cancer diagnosis was obtained by re-contacting case women (or proxy) and retrieving
and abstracting updated medical records (Sagiv et al., 2007). Among women with complete
medical records (n=520), concordance of treatment information based on abstracted medical
records and self-reported treatment was high (kappa = 0.97 for radiation therapy, 0.96 for
chemotherapy, and 0.92 for hormone therapy), and thus the self-reported data are used in the
analysis reported here. Data on complete course of treatment is available for 520 cases.
Statistical Analysis
PAH-DNA adduct levels were log transformed and analyzed as a binary variable (detectable/
not-detectable) and using quintiles with non-detectable adduct levels in the lowest quintile and
then dividing the remaining subjects with detectable adducts into quartiles. For the all-cause
mortality analysis, events (failures) were all deaths between the date of diagnosis and the end
of follow-up (December 31, 2002). Participants that did not die before the end of follow-up
were censored at the end of follow-up. For breast cancer-specific mortality, events were all
deaths due to breast cancer between the date of diagnosis and the end of follow-up. Participants
that died of any other cause before the end of follow-up were censored at their date of death,
and participants that did not die before the end of follow-up were censored at the end of follow-
up.
Hazard ratios (HR) and 95% confidence intervals (CI) were estimated with Cox proportional
hazards models (Allison, 1995), adjusting for covariates described previously (Gammon et al.,
2002b; Gaudet et al., 2004; Shantakumar et al. 2005). Violation of the proportional hazards
assumption was examined for exposure and covariates using log (−log) plots and by inclusion
of a time-dependent interaction variable in the model. Potential confounders evaluated included
age at diagnosis, race and ethnicity, religion, education, household income, marital status,
length of residence in interview home, benign breast disease, family history of breast cancer,
BMI (weight in kilograms/height in meters squared) at reference, age at menarche, hormone
replacement use, menopausal status at diagnosis, oral contraceptive use, age at first birth, parity,
lactation history, history of fertility problems, mammography, active and passive cigarette
smoking, alcohol consumption, dietary intake of grilled and smoked food, fruits and vegetables
and total dietary benzo[a]pyrene intake. Definitions of these covariates were previously
described (Gammon et al., 2002b; Gaudet et al., 2004; Shantakumar et al. 2005). Covariates
were retained in the final model if their inclusion in the multivariable model changed the HR
by more than 10% (Rothman and Greenland, 2005). Effect modification between PAH-DNA
adducts and mortality was assessed for age, ER/PR receptor status, menopausal status, body
mass index (BMI), tobacco and alcohol use. Interaction terms were added to the Cox models
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to estimate HRs across each level of these modifiers and effect modification was assessed
statistically with the likelihood ratio test (Allison, 1995). We also explored possible effect
modification by treatment (radiation, chemotherapy and hormone therapy).
RESULTS
None of the covariates changed the HR by more than 10% and thus only unadjusted and age-
adjusted estimates are presented. We observed a 20% increase in the HR for the association
between detectable PAH-DNA adducts and breast cancer-specific mortality (age-adjusted
HR=1.20, 95% CI: 0.63, 2.28), but the estimate was not statistically significant. In contrast,
for all-cause mortality, we observed a very modest non-statistically significant inverse
association with detectable adduct levels (age-adjusted HR=0.88, 95% CI: 0.57, 1.37); quintile
analyses also showed this inverse pattern, though estimates were imprecise (Table 1).
There was a suggestion of effect modification for all-cause and breast cancer-specific mortality
by several modifiers (Table 2), with higher mortality risk among cases with hormone receptor
negative tumors (ER−/PR−), premenopausal cases, overweight cases, non-smokers and those
exposed to passive cigarette smoke, and alcohol consumers; none of these interactions were
statistically significant, however.
Among the subgroup with information available on complete course of treatment received for
the initial breast cancer (n=520), cases that received radiation therapy had higher PAH-DNA
adduct associations with all-cause and breast cancer-specific mortality (age-adjusted HR
=2.47, 95% CI: 0.74, 8.21, likelihood ratio p-value=0.21 and HR=5.94, 95% CI: 0.80, 44.38,
likelihood ratio p-value<0.01, respectively). In contrast, cases that received hormone therapy
had lower PAH-DNA adduct associations with all-cause and breast cancer mortality (age-
adjusted HR =0.52, 95% CI: 0.24, 1.13, likelihood ratio p-value=0.01 and HR=0.67, 95% CI:
0.25, 1.78, likelihood ratio p-value=0.07, respectively). There was no observed effect
modification between PAH-DNA adducts and mortality by chemotherapy.
DISCUSSION
We did not observe strong associations between PAH-DNA adducts and all-cause or breast
cancer mortality among the LIBCSP cases. There was little evidence for effect modification
of these associations by age at diagnosis, hormone receptor status, menopausal status, BMI,
cigarette smoke or alcohol consumption. Associations were modified by treatment, however,
with more than a doubling in risk of mortality associated with detectable PAH-DNA adducts
among the subgroup who received radiation therapy, but a lower mortality risk due to adducts
among hormone therapy users.
Important predictors of breast cancer survival reported in the literature include stage at
diagnosis and treatment (American Cancer Society, 2004; Chu et al. 1996), with consistent
associations also found for BMI (Tretli et al., 1990; Zhang et al., 1995). To our knowledge,
this is the first study to look at the association between PAH-DNA adducts and mortality among
breast cancer cases. Studies of diet (Zhang et al., 1995; Holmes et al., 1999; Newman et al.,
1986), exogenous hormone use (Holmberg et al., 1994; Reeves et al. 2000), reproductive
history (Daling et al., 2002; Whiteman et al., 2004), physical activity (Holmes et al., 2005;
Rohan et al., 1995) and alcohol consumption (Ewertz et al., 1994; McDonald et al., 2002) are
less conclusive. Though there has been concern that cigarette smoking among women with
breast cancer is associated with survival (Ewertz et al., 1994; Manjer et al., 2000; Vatten et al.,
1991; Yu et al., 1997), we did not find this to be the case in our study (Sagiv et al., 2007). A
significant strength of the current study is that exposure was based on PAH-DNA adducts, a
biomarker of exposure, rather exposure based on self-report, as is the case with cigarette
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smoking. Adduct levels reflect not only exposure dose but the body’s response to the exposure
and is therefore a better measure of body burden (Santella et al. 1999). Further, in a previous
report of the Long Island Breast Cancer Study (Shantakumar et al. 2005), we found that women
with higher adduct levels were more likely to be current or past smokers (OR=1.50, 95%
CI=1.00, 2.24; OR=1.46, 95% CI=1.05, 2.02, respectively) and to have donated blood in
summer and fall (OR=2.65, 95% C =1.69, 4.17; OR=1.59, 95% CI=1.08, 2.32, respectively).
However, PAH from other sources, including food (estimated using a food frequency
questionnaire and self-reports about intake of grilled and smoked foods) and vehicular traffic
(estimated using geographic modeling techniques) were not associated with PAH-DNA
adducts in these data.
The biologic mechanism for the association between PAH-DNA adducts and breast cancer
mortality and the critical window for exposure to factors that lead to PAH-DNA adduct
formation is unclear. PAHs, such as benzo(a)pyrene (BaP) and 7,12-dimethylbenz(a)
anthracene (DMBA), are well known complete carcinogens, capable of both tumor initiation
via genotoxic actions on DNA as well as tumor promotion through non-genotoxic signaling
pathways (Luch, 2005). Thus, it is plausible that PAH exposure could act as a tumor promoter
of cancer cells that eluded eradication during treatment, to increase the risk of tumor
progression and hence mortality among breast cancer survivors.
Care was also taken to draw blood prior to treatment. The LIBCSP is the largest, most
comprehensive study to date to investigate PAH-DNA adducts and breast cancer. Despite the
large sample size, however, this study still had limited power to study mortality, most likely
due to the small number of deaths that occurred over the study period. This was a particular
problem when investigating effect modification as cell sizes were quite small. Treatment data
were available for only a subset of breast cancer cases. This limited study power but probably
did not result in a selection bias since the DNA-PAH adduct-mortality associations remained
the same for the subgroup. Despite power limitations, if a true association between PAH-DNA
adducts and mortality does exist, it is unlikely that this association is strong. Further
investigation is warranted among a larger population with more outcomes, however,
particularly among premenopausal women where PAH-related mortality may be higher.
In contrast to several other investigations (Ford et al., 2003; Neugut et al., 1994), we previously
reported little evidence for an interaction between radiation treatment and smoking on mortality
among women with breast cancer (Sagiv et al., 2007). The current analysis detected a two- to
six-fold increase in mortality for the interaction between radiation therapy and detectable PAH-
DNA adducts. Because the PAH biomarker is a measure of exposure as well as the inherent
individual variability in response to the exposure (Santella et al., 1999), our biomarker results
may identify those who are particularly susceptible to the dual effects of both PAH and
radiation. Another explanation for this finding is that treatment is a reflection of disease stage,
which in turn is a major predictor of survival. Thus, this potential interaction requires further
evaluation in biomarker studies that include larger numbers of breast cancer survivors with
information of stage over a longer period of follow-up.
In summary, these data do not support a strong association between PAH-DNA adducts and
all cause or breast cancer mortality, though effect modification by treatment was observed.
Investigation of modifiable environmental risk factors for breast cancer incidence and mortality
remains a public health priority.
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